We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
Cap. Flow
+$64.9M
Cap. Flow %
3.27%
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65
Avg Time Held Equity + Options
4.7 quarters
Top 10 Avg Time Held Equity + Options
5.1 quarters
Top 20 Avg Time Held Equity + Options
6.3 quarters
Avg Time Held Equity only
4.9 quarters
Top 10 Avg Time Held Equity only
5.1 quarters
Top 20 Avg Time Held Equity only
6.4 quarters

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$46.6M
2
PBYI icon
Puma Biotechnology
PBYI
+$41M
3
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$35.9M
4
CORI
Corium International, Inc.
CORI
+$19M
5
ISRG icon
Intuitive Surgical
ISRG
+$17.9M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$37.6M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.2M
3
NVRO icon
NEVRO CORP.
NVRO
+$20.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.3M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.26%
2 Miscellaneous 3.45%
3 Consumer Staples 0.19%
4 Consumer Discretionary 0.06%
5 Energy 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SYRE icon
151
Spyre Therapeutics
SYRE
$7.52B
– –
-233
Closed -$43K –
TXMD icon
152
TherapeuticsMD
TXMD
$22.7M
– –
-22
Closed -$8K –
WST icon
153
West Pharmaceutical
WST
$26.2B
– –
-138
Closed -$11K –
NVRO icon
154
DELISTED
NEVRO CORP.
NVRO
– –
-217,292
Closed -$20.4M –
RCM icon
155
DELISTED
R1 RCM Inc. Common Stock
RCM
– –
-17,976
Closed -$56K –
TCON
156
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
– –
0
– –
2017 Q2
0 quarters
MDRX
157
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-42,955
Closed -$545K –
NXGN
158
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
– –
-33,875
Closed -$516K –
CYTO icon
159
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-5
Closed -$368K –
ZYNE
160
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-251,328
Closed -$5M –
ISEE
161
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,600
Closed -$5K –
BLCM
162
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-8,620
Closed -$1.06M –
AGRX
163
DELISTED
Agile Therapeutics
AGRX
– –
0
– –
2017 Q2
0 quarters
ABMD
164
DELISTED
Abiomed Inc
ABMD
– –
-85,000
Closed -$10.6M –
CLVS
165
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-157,754
Closed -$10M –
AERI
166
DELISTED
Aerie Pharmaceuticals
AERI
– –
-50,000
Closed -$2.27M –
EPZM
167
DELISTED
Epizyme, Inc
EPZM
– –
-1,165
Closed -$20K –
PRAH
168
DELISTED
PRA Health Sciences, Inc.
PRAH
– –
-8,308
Closed -$542K –
FPRX
169
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-127
Closed -$5K –
HMSY
170
DELISTED
HMS Holdings Corp.
HMSY
– –
-26,553
Closed -$540K –
AMAG
171
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-560,000
Closed -$12.6M –
IMMU
172
DELISTED
Immunomedics Inc
IMMU
– –
-300,060
Closed -$1.94M –
AKRX
173
DELISTED
Akorn Inc
AKRX
– –
-40,000
Closed -$963K –
QHC
174
DELISTED
Quorum Health Corporation
QHC
– –
-50,604
Closed -$275K –
RARX
175
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-100,000
Closed -$2.13M –
4 5 6
7
8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $64.9M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.

  • Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
  • Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
  • Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
  • Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
  • Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.